HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation
Broad scientific visibility across multiple programs, disease areas, and immune contexts reflects sustained execution and expanding external recognition in 2026
[Taipei, Shanghai, San Francisco | April 20, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.
Through H1 2026, HanchorBio has delivered or secured a diverse set of scientific presentations spanning its lead clinical and translational programs, including HCB101 monotherapy, HCB101 combination therapy, HCB301, and HCB206. These presentations reflect the Company’s continued progress in building clinical and translational evidence for its proprietary FBDB™ platform and its strategy to develop differentiated immune backbones and multifunctional biologics across oncology and autoimmune diseases.
“Strong and sustained scientific visibility matters because it reflects both execution and relevance,” said Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (U.S.A.) of HanchorBio. “Our H1 2026 conference activity demonstrates that HanchorBio is continuing to generate and communicate meaningful clinical and translational data across multiple programs, disease areas, and presentation formats. Importantly, we are not only reporting continued progress in oncology, but also extending visibility beyond oncology as our platform advances across broader immune-mediated settings.”
During Q1 2026, HanchorBio delivered a strong series of presentations across key international meetings, including ESMO-TAT, ESTRO/ICHNO, ASCO-GI, AACR-IO, APGCC, and TSITC. In total, the Company delivered 10 presentations in Q1 2026, including 4 oral presentations, 5 posters, and 1 symposium presentation.
Following a strong Q1 2026 conference season, HanchorBio is continuing to build scientific visibility in Q2 2026 through participation in 7 conferences, representing 11 abstracts, 1 symposium presentation, and 1 keynote speaker invitation across multiple programs and disease areas. Confirmed Q2 activities to date include presentations at GBCC, TJCC, the ASCO Annual Meeting, and FOCiS, while submissions to EMSO-TAT Asia, ASCO Breakthrough, and JCA-AACR remain under review. These submissions span multiple areas, including gastric cancer, colorectal cancer, head and neck cancer, TNBC, and immuno-oncology-focused translational work, and immune biology beyond oncology. The FOCiS late-breaking abstract, in particular, highlights the clinical and translational validation of selective CD47-SIRPα engineering across both oncology and autoimmunity, including HCB206 data in an SLE patient-derived PBMC-engrafted humanized model.
H1 2026 Scientific Communications Highlights
- 10 presentations delivered in Q1 2026
- 5 presentations accepted or scheduled and 7 abstracts pending in Q2 2026
- 4 programs represented: HCB101 monotherapy, HCB101 combination therapy, HCB301, and HCB206
- Scientific visibility expanded beyond oncology into autoimmune and broader immune-related biology
The Company’s 2026 scientific communications activities to date have supported visibility across multiple tumor areas, broader immunology settings, and translational disease contexts, and are intended to reinforce the evolving clinical and translational profile of HanchorBio’s pipeline.
“HanchorBio’s conference activity in 2026 reflects a disciplined scientific communications strategy aligned with the progress of our pipeline,” said Scott Liu, PhD, Founder, Chairman, and Chief Executive Officer of HanchorBio. “We believe continued visibility at major medical meetings is important not only for scientific exchange, but also for demonstrating the breadth, consistency, and growing maturity of our development programs. We are pleased to see this momentum continuing into Q2 and potentially through the second half of the year.”
About HCB101
HCB101 is an AI-guided (AlphaFold) structurally engineered SIRPα-IgG4 Fc fusion protein designed to selectively target the CD47-SIRPα innate immune checkpoint while reducing hematologic toxicity associated with earlier CD47-targeting therapies. The program is being developed as a differentiated innate immune backbone with broad combination potential across multiple tumor types and therapeutic settings.
About HCB301
HCB301 is a tri-specific fusion protein designed to integrate modulation of the CD47/SIRPα, PD-1/PD-L1, and TGFβ/ TGFβ-R pathways within a single molecule. By simultaneously addressing multiple interdependent mechanisms of immune resistance, the program reflects HanchorBio’s broader strategy to develop multifunctional biologics with the potential to deliver more coordinated and clinically meaningful immune modulation.
About HCB206
HCB206 is designed to extend HanchorBio’s selective CD47-SIRPα engineering approach beyond oncology into the field of autoimmune disease. By combining targeted B-cell depletion with an engineered innate immune mechanism intended to minimize unwanted hematologic effects, HCB206 reflects the broader versatility of HanchorBio’s platform across diverse immune-mediated disease settings.
About HanchorBio
HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on developing next-generation immunotherapies for oncology and autoimmune diseases. With operations in Taipei, Shanghai, and San Francisco, the Company is advancing a portfolio of differentiated biologics enabled by its proprietary FBDB™ (Fc-Based Designer Biologics) platform. HanchorBio’s pipeline is designed to address complex disease biology through rationally engineered molecules with the potential to activate both innate and adaptive immune pathways.
漢康生技報告2026年上半年科學溝通成果，並預告第二季將參與多項學術會議
橫跨多項計畫、疾病領域與免疫研究主題的科學交流布局，展現公司於2026年持續推進研發並持續獲得外部肯定
【台北、上海、舊金山｜2026年4月20日】——漢康生技，一家致力於開發腫瘤及自體免疫疾病次世代免疫療法的全球臨床階段生技公司，今日宣布，2026年上半年公司持續展現穩健的科學溝通動能，已於多個國際學術會議進行口頭報告、小型口頭報告、專題研討會、主題演講及海報展示。公司亦同步預告2026年第二季已獲接受或預計參與的學術會議，彰顯其在多項計畫、疾病領域及轉譯醫學場景中的外部能見度。
2026年上半年，漢康生技已完成或獲接受多項科學報告，內容涵蓋公司主要臨床及轉譯計畫，包括HCB101單一療法、HCB101合併療法、HCB301及HCB206。這些成果反映出公司持續為其專有FBDB™平台累積臨床與轉譯證據，並推進其在腫瘤及自體免疫疾病領域開發差異化免疫骨幹療法及多功能生物藥的整體策略。
「持續而穩健的科學能見度相當重要，因為這不僅反映執行力，也代表研究內容具備臨床與科學上的關聯性，」漢康生技集團總裁兼首席醫療長、美國子公司執行長陸英明博士表示。「2026年上半年的會議活動顯示，漢康生技正持續產出並傳遞具有意義的臨床與轉譯數據，涵蓋多項計畫、不同疾病領域及多元報告形式。更重要的是，除腫瘤領域的持續進展外，隨著平台逐步拓展至更廣泛的免疫相關疾病，我們的科學能見度也已延伸至腫瘤以外的研究領域。」
2026年第一季，漢康生技已於多個重要國際會議發表研究成果，包括歐洲腫瘤內科學會標靶抗癌治療大會（ESMO-TAT）、歐洲放射腫瘤學會暨國際頭頸腫瘤放射治療會議（ESTRO/ICHNO）、美國臨床腫瘤學會胃腸道癌症研討會（ASCO-GI）、美國癌症研究學會免疫腫瘤學會議（AACR-IO）、亞太胃癌會議（APGCC）及台灣腫瘤免疫學會年會（TSITC）。總體來說，公司於2026年第一季共完成10場報告，包括4場口頭報告、5場海報展示及1場專題研討會報告。
延續第一季的科學交流成果，漢康生技預計於第二季參與7場學術會議，預計涵蓋呈現11篇摘要、1場專題研討會報告及1場主題演講邀請，橫跨多項計畫與疾病領域。目前已確認的第二季活動包括於全球乳癌會議（GBCC, Global Breast Cancer Conference）、台灣癌症聯合年會（TJCC, Taiwan Joint Cancer Conference）、美國臨床腫瘤學會年會（ASCO Annual Meeting）及國際臨床免疫學聯合會年會（FOCiS, Federation of Clinical Immunology Societies Annual Meeting）進行報告。
這些已接受或提交中的摘要主題涵蓋胃癌、大腸直腸癌、頭頸癌、三陰性乳癌、以腫瘤免疫為核心的轉譯研究，以及腫瘤以外的免疫生物學研究。其中，於FOCiS獲接受的突破性研究摘要，進一步凸顯選擇性CD47-SIRPα工程化策略在腫瘤及自體免疫領域的臨床與轉譯驗證潛力，包括HCB206於全身性紅斑性狼瘡患者來源PBMC移植人源化模型中的研究數據。
2026年上半年學術及臨床會議亮點
- 2026年第一季完成10場報告
- 2026年第二季已接受或安排5場報告，另有7篇摘要待審
- 涵蓋4項計畫：HCB101單一療法、HCB101合併療法、HCB301及HCB206
- 由腫瘤領域延伸至自體免疫及更廣泛的免疫相關生物學領域
整體而言，漢康生技2026年迄今的學術及臨床會議，已逐步擴展公司在多個腫瘤適應症、更廣泛免疫學背景及轉譯疾病研究場景中的能見度，並進一步強化其產品管線不斷演進的臨床與轉譯定位。
「漢康生技2026年的會議布局，展現其科學溝通策略與產品線推進進程之間的高度一致性，」漢康生技創辦人、董事長兼執行長劉世高博士表示，「我們相信，持續在重要國際醫學會議上發表成果，不僅有助於科學交流，也能更完整呈現公司開發計畫的廣度、一致性與逐步成熟的進展。我們樂見這股動能延續至第二季，並持續推進下半年的研發與學術交流工作。」
關於 HCB101
HCB101 為漢康生技以 FBDB™ 平台理性設計開發之 SIRPα–IgG4 Fc 融合蛋白，旨在選擇性阻斷 CD47–SIRPα 先天免疫檢查點，同時降低血液學毒性。不同於早期的抗 CD47，HCB101 在保留巨噬細胞介導抗腫瘤活性的同時，降低對紅血球 CD47 的結合能力，以克服過去限制該療法發展的關鍵挑戰。
透過 AI 輔助結構建模，HCB101 對腫瘤細胞上的 CD47 具差異化結合特性，並維持對紅血球 CD47 的低親和力。其安全性、受體佔有率與藥理特性，皆有利於與既有腫瘤治療方案整合。目前 HCB101 正於胃癌、大腸直腸癌及頭頸癌等適應症持續進行劑量遞增與臨床二期擴展研究。
綜合上述特質，HCB101 已定位為具備差異化的先天免疫檢查點骨幹（Backbone），並具備橫跨實體腫瘤與血液腫瘤的廣泛潛力。
關於HCB301
HCB301是一款三特異性融合蛋白，亦由FBDB™ 平台設計開發，旨在單一分子中整合對CD47/SIRPα、PD-1/PD-L1及TGFβ/TGFβ-R路徑的調節。透過同時應對多種相互依賴的免疫抵抗機制，該計畫反映了漢康生技開發多功能生物藥、以實現更協調且具有臨床意義的免疫調節的更廣泛策略。
關於HCB206
HCB206亦由FBDB™ 平台設計開發，旨在將漢康生技的選擇性CD47-SIRPα工程化方法從腫瘤領域拓展至自體免疫疾病領域。透過將靶向B細胞清除與旨在減少非預期血液學影響的工程化先天免疫機制相結合，HCB206反映了漢康生技平台在多種免疫媒介疾病場景中的廣泛適用性。
關於漢康生技
漢康生技（股票代碼：7827.TPEx）是一家全球臨床階段的生物技術公司，專注於開發腫瘤及自體免疫疾病的下一代免疫療法。公司在台北、上海及舊金山設有營運據點，正在推進一系列差異化生物藥管線，這些藥物由其專有的FBDB™平台賦能。漢康生技的產品線旨在透過理性設計的分子應對複雜的疾病生物學，這些分子具有激活先天與適應性免疫通路的潛力。